Pure Cannabis Research AG is now Puregene

Press Release: 03. Nov. 2019

While our name may have changed, our mission has not. Puregene creates the highest quality, non-GMO, novel genetics for the next generation of highly productive cannabis in a dynamic global marketplace.

While our name may have changed, our mission has not. Puregene creates the highest quality, non-GMO, novel genetics for the next generation of highly productive cannabis in a dynamic global marketplace.

Puregene operates a research-first, data-driven, genomics-based molecular breeding program designed for rapid and accurate development of high-performance and tailored varieties. The research at Puregene allows for the identification of cannabis traits and the DNA sequences which produce them. The genomics technology at Puregene is maintained at the cutting edge through our close partnership with NRGene, Israel, where we have produced the world’s first true fully phased, super-pangenome of cannabis and the second for any crop plant. Working with renowned academics, such as Prof. Bruno Studer of the ETH Zurich in Switzerland, a leader in advanced molecular breeding, Puregene has been able to implement the most modern breeding toolset available. This breeding is further enabled through our collaboration with Prof. Jens Kossmann, Director of the Institute for Plant Biotechnology at the University of Stellenbosch and a leader in the field of plant metabolism, where we have been granted a license to research THC-containing varieties and better understand the genetic basis of their productivity with respect to cannabinoid production. Empowered with these expert partners, proprietary genomes and equipped with a cutting-edge molecular laboratory and breeding program, a dedicated breeding station, and the expertise from a team of PhD and graduate researchers from around the world, Puregene is ready to tackle the challenges of cannabis research facing the industry today and into the future.

These technologies have already enabled the development of highly productive and importantly, novel, varieties. These include our headline variety for 2020, Pure CBG. The cannabinoid CBG is prized for its energizing effect and reported antimicrobial properties. Considered the “mother of all cannabinoids”, because all others stem from this one molecule. CBG provides a unique experience which can be likened to the relaxing effect of CBD, but without the sleepiness leaving an effect that is stimulating, uplifting and energetic. This highly productive, high-resin type variety produces in excess of 5% CBG in multiple large flowers, just as in current CBD varieties. Critically, THC is extremely low at far less than 0.1 %. Pure CBG will be available as clones and also as seed, which we will be producing in the millions for the 2020 growth season.

Puregene has developed a global network for production and distribution of our elite genetics. US Nursery is a leader in cannabis propagation and research in the United States. A strategic alliance between Puregene and US Nursery has enabled the establishment of the first legal transfer of cannabis between Europe and the United States. Our established pipeline now allows for the transfer of both in vitro as well as clonal cuttings. This allows American producers to produce both market-tested and novel Swiss varieties. Puregene varieties have been bred with the Swiss philosophy of quality and dependability and have been constructed under the Swiss advantage of early regulatory clarity putting our variety development years ahead of the US and EU countries. Together with US Nursery, producers in the United States will be able to grow stable, tested, productive cannabis that is fully tracible and fully legally compliant providing the peace of mind required to focus on growing their businesses.